tirzepatide weight loss program michigan for Patients Tirzepatide on ingestive behavior in

Consider protein shakes on days when solid food intake is particularly low

Tirzepatide (Mounjaro, Zepbound) is a peptide-based prescription drug that acts as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes management and chronic weight management

no matter what I did, I would gain weight

The Phase 2a MASLD readout published in Nature Medicine in 2024 reported dose-dependent reductions in liver fat content across the same dose range (Sanyal et al., Nature Medicine, 2024)

Nausea occurs in about 40% to 45% of people on tirzepatide at maximum doses versus 30% to 44% with semaglutide

Patients should be instructed to report severe or persistent vomiting, as this may lead to dehydration, electrolyte disturbances, and acute kidney injury requiring medical attention